Search Results - "MITCHELL, David Y"

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers by Becker, Andreas, Martin, Emily C., Mitchell, David Y., Grenningloh, Roland, Bender, Andrew T., Laurent, Julien, Mackenzie, Harald, Johne, Andreas

“…Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This…”
Get full text

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer by RINEHART, John, ADJEI, Alex A, GULYAS, Stephen, MITCHELL, David Y, HERRERA, Roman, SEBOLT-LEOPOLD, Judith S, MEYER, Mark B, LORUSSO, Patricia M, WATERHOUSE, David, HECHT, J. Randolph, NATALE, Ronald B, HAMID, Oday, VARTERASIAN, Mary, ASBURY, Peggy, KALDJIAN, Eric P

“…This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal…”
Get full text

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies by Lorusso, Patricia M, Adjei, Alex A, Varterasian, Mary, Gadgeel, Shirish, Reid, Joel, Mitchell, David Y, Hanson, Lorelei, DeLuca, Pamela, Bruzek, Laura, Piens, Jill, Asbury, Peggy, Van Becelaere, Keri, Herrera, Roman, Sebolt-Leopold, Judith, Meyer, Mark B

“…This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a…”
Get full text

Patient characteristics and patterns of drug use for sleep complaints in the united states: Analysis of national ambulatory medical survey data, 1997–2002 by Morlock, Robert J., Tan, Maudrene, Mitchell, David Y.

“…The aims of this work were to characterize ambulatory patients in the United States presenting with primary or secondary insomnia complaints and resultant…”
Get full text

Relationship between age, renal function and bone mineral density in the US population by KLAWANSKY, Sidney, KOMAROFF, Eugene, CAVANAUGH, Paul F, MITCHELL, David Y, GORDON, Matthew J, CONNELLY, Janet E, ROSS, Susan D

“…Bisphosphonate drugs for treating osteoporosis are excreted by the kidney. However, many of the major trials on efficacy and safety of the bisphophonates for…”
Get full text

The Patient‐Centered Future of Clinical Pharmacology by Shahin, Mohamed H., Abdel‐Rahman, Susan, Hartman, Dan, Johnson, Julie A., Mitchell, David Y., Reynolds, Kellie S., Wagner, John A., Morrissey, Kari M.

Get full text

Correction to Discovery of the Hemifumarate and (α‑l‑Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group by Robinson, Ralph P, Reiter, Lawrence A, Barth, Wayne E, Campeta, Anthony M, Cooper, Kelvin, Cronin, Brian J, Destito, Rosalina, Donahue, Kathleen M, Falkner, Fred C, Fiese, Eugene F, Johnson, Diane L, Kuperman, Alexander V, Liston, Theodore E, Malloy, Deborah, Martin, John J, Mitchell, David Y, Rusek, Frank W, Shamblin, Sheri L, Wright, Charles F

Get full text

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma by Lin, Shi-Ming, Lu, Sheng-Nan, Chen, Ping-Tsung, Jeng, Long-Bin, Chen, Shinn-Cherng, Hu, Chi-Tan, Yang, Sien-Sing, Le Berre, Marie-Aude, Liu, Xuan, Mitchell, David Y., Prins, Klaas, Grevel, Joachim, Peña, Carol A. E., Meinhardt, Gerold

“…Background Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib…”
Get full text

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration by MITCHELL, David Y, BARR, William H, EUSEBIO, Rachelle A, STEVENS, Karen A, DUKE, Frank P, RUSSELL, Darrell A, NESBITT, John D, POWELL, James H, THOMPSON, Gary A

“…To determine the pharmacokinetics and absolute bioavailability of risedronate after single-dose oral administration of 30 mg risedronate as a tablet and an…”
Get full text

The effect of dosing regimen on the pharmacokinetics of risedronate by MITCHELL, D. Y, HEISE, M. A, PALLONE, K. A, CLAY, M. E, NESBITT, J. D, RUSSELL, D. A, MELSON, C. W

“…Aims To examine the effect of timing of a risedronate dose relative to food intake on the rate and extent of risedronate absorption following single‐dose, oral…”
Get full text

Dose-Proportional Pharmacokinetics of Risedronate on Single-Dose Oral Administration to Healthy Volunteers by Mitchell, David Y., Eusebio, Rachelle A., Sacco-Gibson, Nancy A., Pallone, Karen A., Kelly, Sandra C., Nesbitt, John D., Brezovic, Christopher P, Thompson, Gary A., Powefl, James H.

“…Risedronate is a pyridinyl bisphosphonate approved for the treatment of Paget's disease (US‐FDA) and in development for the treatment and prevention of…”
Get full text

Discovery of the Hemifumarate and (α-l-Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole:  Prodrugs for the Enolic OH Group by Robinson, Ralph P, Reiter, Lawrence A, Barth, Wayne E, Campeta, Anthony M, Cooper, Kelvin, Cronin, Brian J, Destito, Rosalina, Donahue, Kathleen M, Falkner, Fred C, Fiese, Eugene F, Johnson, Diane L, Kuperman, Alexander V, Liston, Theodore E, Malloy, Deborah, Martin, John J, Mitchell, David Y, Rusek, Frank W, Shamblin, Sheri L, Wright, Charles F

“…Ether, ester, and carbonate derivatives of the antirheumatic oxindole 1 were prepared and screened as potential prodrugs of 1. This effort led to the discovery…”
Get full text

Risedronate gastrointestinal absorption is independent of site and rate of administration by MITCHELL, D. Y, EUSEBIO, R. A, DUNLAP, L. E, PALLONE, K. A, NESBITT, J. D, RUSSELL, D. A, CLAY, M. E, BEKKER, P. J

“…Two studies were conducted to compare the absorption of risedronate administered as a solution to three different gastrointestinal sites (study A) and to…”
Get full text

Oxidation of aldehydic products of lipid peroxidation by rat liver microsomal aldehyde dehydrogenase by Mitchell, D Y, Petersen, D R

“…Lipid peroxidation in microsomal membranes produces a large number of aldehydes, alcohols, and ketones, some of which have been shown to be cytotoxic. This…”
Get more information

Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial by Bastholt, Lars, Brose, Marcia S., Jarzab, Barbara, Schlumberger, Martin, Siena, Salvatore, De La Fouchardiere, Christelle, Paschke, Ralf, Deshpande, Hari Anant, Shi, Yuankai, Elisei, Rossella, Gao, Ming, Li, Lin, Prins, Klaas, Walker, Helen, Mitchell, David Y., Lettieri, John T., Molnar, Istvan, Kappeler, Christian, Pena, Carol Elaine

“…Abstract only…”
Get full text

Phase i and pharmacodynamic study of the oral MEK inhibitor Cl-1040 in patients with advanced malignancies : Signal transduction by LORUSSO, Patricia M, ADJEI, Alex A, ASBURY, Peggy, VAN BECELAERE, Keri, HERRERA, Roman, SEBOLT-LEOPOLD, Judith, MEYER, Mark B, VARTERASIAN, Mary, GADGEEL, Shirish, REID, Joel, MITCHELL, David Y, HANSON, Lorelei, DELUCA, Pamela, BRNZEK, Laura, PIENS, Jill

Get full text

The oxidation of alpha-beta unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydrogenases by Mitchell, D Y, Petersen, D R

“…Lipid peroxidation of microsomal membranes produces a large number of aldehydes, alcohols, and ketones, of which some are cytotoxic. trans-4-Hydroxy-2-nonenal…”
Get more information

Dose-Proportional Pharmacokinetics of Risedronate on Single-Dose Oral Administration to Healthy Volunteers by Mitchell, David Y, Eusebio, Rachelle A, Sacco-Gibson, Nancy A, Pallone, Karen A, Kelly, Sandra C, Nesbitt, John D, Brezovic, Christopher P, Thompson, Gary A, Powell, James H

“…Risedronate is a pyridinyl bisphosphonate approved for the treatment of Paget's disease (US-FDA) and in development for the treatment and prevention of…”
Get full text

Future Innovation

“…Three presidents of leading pharmaceutical associations provide their take on the future of the industry, with a focus on where medical discoveries and…”
Get full text